CHMP backs Zepzelca plus Tecentriq in first-line ES-SCLC
Immedica has disclosed a positive CHMP recommendation for Zepzelca, or lurbinectedin, in combination with Roche’s Tecentriq, or atezolizumab, as first-line maintenance therapy for adults with extensive-stage small cell lung cancer after induction treatment with atezolizumab, carboplatin, and etoposide. The opinion marks a key regulatory milestone in Europe for a regimen that has been gaining momentum since phase 3 data from IMforte showed a survival advantage over maintenance atezolizumab alone. (ema.europa.eu)
The backdrop is a disease setting where progress has been limited. Tecentriq already holds an EU indication in combination with carboplatin and etoposide for first-line ES-SCLC, but maintenance options after induction have remained thin. Lurbinectedin first established itself in relapsed small cell lung cancer, then moved earlier in treatment through the IMforte program, which evaluated whether adding it to maintenance immunotherapy could extend benefit after standard induction chemoimmunotherapy. EMA records also show the extension-of-indication procedure for lurbinectedin maintenance in ES-SCLC entered CHMP evaluation in late 2025, underscoring that this recommendation is the culmination of a formal European review process. (ema.europa.eu)
The pivotal evidence came from the randomized, open-label phase 3 IMforte trial. Patients first received four 21-day cycles of atezolizumab, carboplatin, and etoposide; those without progression were randomized to maintenance atezolizumab plus lurbinectedin or atezolizumab alone. Roche reported that, from randomization, median overall survival was 13.2 months with the combination versus 10.6 months with atezolizumab alone, with a hazard ratio of 0.73. Median progression-free survival was 5.4 months versus 2.1 months, with a hazard ratio of 0.54. The study enrolled 660 patients in induction and randomized 483 into maintenance, and the company said no new safety signals emerged. Roche’s materials cite the full IMforte report as published in The Lancet in June 2025. (assets.roche.com)
Industry and expert framing has been notably consistent. Roche called the findings a significant survival benefit, while IMforte principal investigator Luis Paz-Ares said earlier top-line results were highly encouraging and showed a statistically significant benefit for the combination in the first-line maintenance setting. Independent oncology coverage around ASCO 2025 went further, describing IMforte as the first phase 3 study to demonstrate a meaningful overall survival improvement with first-line maintenance therapy in ES-SCLC. That matters because small cell lung cancer has long been characterized by rapid relapse and a short list of therapies that move survival in a clinically meaningful way. (roche.com)
Why it matters: For oncology practices, the CHMP recommendation signals that Europe may soon add a maintenance regimen that can change the post-induction conversation for eligible ES-SCLC patients. In practical terms, this could reshape sequencing after frontline chemoimmunotherapy, expand demand for infusion-center capacity during maintenance, and prompt updates to treatment pathways, pharmacy protocols, and reimbursement planning if the European Commission grants final approval. The U.S. FDA already approved the regimen in October 2025, suggesting regulators on both sides of the Atlantic see the IMforte data as practice-changing. (roche.com)
There’s also a commercial and geographic dimension. Immedica markets Zepzelca in parts of Europe, the Middle East, and North Africa, and the company has already announced a UAE approval for the same maintenance use. A positive EU decision would broaden that footprint and could accelerate country-level access discussions, though actual uptake will still depend on pricing and reimbursement timelines that vary across member states. That means the CHMP opinion is important, but it’s not the last operational hurdle before patients can receive the regimen. (immedica.com)
What to watch: The immediate next step is the European Commission’s final decision on the CHMP recommendation. After that, the key questions will be label wording, launch timing across EU markets, and how quickly national payers and guideline bodies incorporate the maintenance combination into routine care. (ema.europa.eu)